trial

An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

NCTId NCT01895452
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 291 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2016-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
291 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-07
Primary completion
2016-06
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
ALKS 9072, Low DoseALKS 9072, High Dose

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
Robert Risinger, MDStudy Director

Sites

57 total
Little Rock, United StatesLittle Rock, United StatesGarden Grove, United StatesOakland, United StatesOceanside, United StatesOrange, United StatesWashington D.C., United StatesFort Lauderdale, United StatesLeesburg, United StatesAtlanta, United StatesChicago, United StatesChicago, United States

Linked catalysts

1
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) — primary completion2016-06

Facts & assertions

4 sourced
Enrollment
291
Phase
PHASE3
Primary Completion Date
2016-06
Status
COMPLETED
relationships
The graph out of here
drug
ALKS 9072, Low Dose
drug
ALKS 9072, High Dose
drug
lead_sponsor
Alkermes, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Robert Risinger, MD
person